share_log

Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target

Benzinga ·  Mar 22 13:51

Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment